Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) for the reporting date of June 16, 2016. The filing addresses a specific regulatory event regarding the company's stock listing status on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a compliance event rather than financial performance.
Material Changes
The primary material change reported is the restoration of compliance with NASDAQ listing requirements:
- Event: Regained compliance with the $1.00 minimum closing bid price requirement (NASDAQ Listing Rule 5550(a)(2)).
- Duration: The closing bid price remained at or above $1.00 per share for 10 consecutive business days (May 31, 2016, to June 15, 2016).
- Outcome: The NASDAQ Listing Qualifications Staff notified the Company that the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No new risks or contingencies are disclosed beyond the resolution of the prior listing deficiency.
Investor Verification Checklist
- Verify the current stock price to ensure continued compliance with the $1.00 minimum bid requirement.
- Confirm the company's name discrepancy between the metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing header ("ONCOGENEX PHARMACEUTICALS, INC.").
- Review subsequent filings to ensure no new listing deficiencies have arisen since June 16, 2016.